<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2019-4-449-453</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-1075</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОФТАЛЬМОХИРУРГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPHTHALMOSURGERY</subject></subj-group></article-categories><title-group><article-title>Хирургическое лечение макулярного разрыва без тампонады витреальной полости</article-title><trans-title-group xml:lang="en"><trans-title>Surgical Treatment of Macular Hole without Postoperative Vitreous Cavity Tamponade</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9569-5906</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клейменов</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazaykin</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, заведующий отделением витреоретинальной хирургии</p><p>ул. Академика Бардина, 4а, Екатеринбург, 620149, Российская Федерация</p></bio><bio xml:lang="en"><p>MD, head of vitreoretinal department</p><p>A. Bardina str., 4A, Ekaterinburg, 620149, Russian Federation </p></bio><email xlink:type="simple">kley_82@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1848-1207</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казайкин</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kleymenov</surname><given-names>A. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач‑офтальмолог</p><p>ул. Академика Бардина, 4а, Екатеринбург, 620149, Российская Федерация</p><p> </p></bio><bio xml:lang="en"><p>Ophthalmologist</p><p>A. Bardina str.,. 4A, Ekaterinburg, 620149, Russian Federation </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7019-3002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лизунов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lizunov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач‑офтальмолог</p><p>ул. Академика Бардина, 4а, Екатеринбург, 620149, Российская Федерация </p></bio><bio xml:lang="en"><p>Ophthalmologist</p><p>A. Bardina str.,. 4A, Ekaterinburg, 620149, Russian Federation </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>АО «Екатеринбургский центр МНТК “Микрохирургия глаза”»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>IRTC Eye Microsurgery Ekaterinburg Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>24</day><month>12</month><year>2019</year></pub-date><volume>16</volume><issue>4</issue><fpage>449</fpage><lpage>453</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Клейменов А.Ю., Казайкин В.Н., Лизунов А.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Клейменов А.Ю., Казайкин В.Н., Лизунов А.В.</copyright-holder><copyright-holder xml:lang="en">Kazaykin V.N., Kleymenov A.U., Lizunov A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/1075">https://www.ophthalmojournal.com/opht/article/view/1075</self-uri><abstract><sec><title>Цель</title><p>Цель: представить технику хирургического лечения макулярного разрыва (МР) без использования тампонады витреальной полости газом или другим заменителем стекловидного тела. </p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. Частота заболевания — 3 случая на 10 000, чаще после 55 лет — 3–3,3 случая на 1000, а пик приходится на возраст 60 лет и старше. По современным данным, частота закрытия МР после витреальной хирургии варьирует от 68 до 98 %. В настоящем исследовании представлены результаты лечения 16 пациентов (16 глаз) со сквозным макулярным разрывом размерами от 100 до 932 мкм (558,5 ± 50,9). Острота зрения составила от 0,04 до 0,2 (0,09 ± 0,01) с коррекцией. Время наблюдения за пациентами, прооперированными по данной технологии, составило от 2 недель до 4 месяцев (9,0 ± 6,3). </p></sec><sec><title>Результаты</title><p>Результаты. Операционных и послеоперационных осложнений ни в одном случае не было. В результате хирургического лечения полное закрытие макулярного разрыва и анатомическое восстановление макулы достигнуто у 15 из 16 пациентов, что соответствует 92,8 %. Острота зрения после операции составила от 0,2 до 0,6 (0,4 ± 0,04) с коррекцией. Рецидив в одном случае был связан с нарушением технологии операции, при котором произошло частичное механическое смещение пленки фибрина канюлей при замене ПФОС на воздух. </p></sec><sec><title>Выводы</title><p>Выводы. Предлагаемый метод хирургического лечения макулярного разрыва без использования послеоперационной тампонады витреальной полости газом или каким-либо другим заместителем стекловидного тела может быть использован в повседневной врачебной практике. Преимущества предложенного метода: не требуется вынужденное положение пациента лицом вниз; зрение после операции в 1-й день находится на предоперационном уровне или выше; снижается риск развития катаракты и повышения ВГД в послеоперационном периоде; сохраняется возможность перелетов и подъема на высоту в раннем послеоперационном периоде.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose. To present the technique of macular hole surgery without vitreous cavity tamponade with gas or another vitreous substitute in post-op period. </p></sec><sec><title>Patients and Methods</title><p>Patients and Methods. Frequency of the disease is 3 cases per 10,000, more often after 55 years — 3–3.3 cases per 1000, and the peak occurs at the age of 60 years and older. According to current data, the frequency of closure MH after vitreous surgery varies from 68 to 98 %. Sixteen eyes of 16 patients were operated on for full-thickness macular holes 100 to 932 (558.5 ± 50.9) microns in diameter. BCVA was 0.04 to 0.2 (0.09 ± 0.01). Follow-up period of the patients was 9 ± 6.3 weeks.</p></sec><sec><title>Results</title><p>Results. No intraoperative and postoperative complications were seen. In the result of surgery complete closure of the macular hole and anatomical restoration of the macula was achieved in 15 of 16 cases (92.8%). Postoperative BCVA was 0.2 to 0.6 (0.4 ± 0.04). A recurrence in one case was associated with a violation of operation technology when a partial mechanical displacement of the fibrin film with a cannula during PFCL exchange for air occurred. </p></sec><sec><title>Conclusions</title><p>Conclusions. The suggested method of macular hole surgery without postoperative tamponade of the vitreous cavity with gas or another vitreous substitute may be used in routine clinical practice: Without face down positioning, reduced risk of cataract and increased IOP, air flight and climb to a height in the early post-op period. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>макулярный разрыв</kwd><kwd>обогащенная тромбоцитами плазма крови</kwd><kwd>тампонирующее вещество</kwd><kwd>витрэктомия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Macular hole</kwd><kwd>platelet-rich blood plasma</kwd><kwd>plugging substance</kwd><kwd>vitrectomy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бикбов М.М., Файзрахманов Р.Р. Влияние антивазопролиферативной терапии на морфофункциональные особенности классической хориоидальной неоваскуляризации у пациентов с возрастной макулярной дегенерацией. Вестник Российской Военно-медицинской академии. 2016;54(2):111–115.</mixed-citation><mixed-citation xml:lang="en">Bikbov M.M., Fajzrahmanov R.R. Influence of antivasoprolipherative therapy on morphological and functional features classic choroidal neovascularization in patients with age‑related macular degeneration. Vestnik of russian military medical academy = Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2016;54(2):111–115 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly N.E., Wendel R.T. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol. 1991;109(5):654–659. DOI: 10.1097/00006982‑199111040‑00026</mixed-citation><mixed-citation xml:lang="en">Kelly N.E., Wendel R.T. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol. 1991;109(5):654–659. DOI: 10.1097/00006982‑199111040‑00026</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ezra E., Gregor Z.J. Surgery for idiopathic full‑thickness macular hole: two‑year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Morfields Macular Hole Study Group RAeport no 1. Arch Ophthalmol. 2004;122(2):224–236. DOI: 10.1097/01.ieb.0000142782.97667.fc</mixed-citation><mixed-citation xml:lang="en">Ezra E., Gregor Z.J. Surgery for idiopathic full‑thickness macular hole: two‑year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Morfields Macular Hole Study Group RAeport no 1. Arch Ophthalmol. 2004;122(2):224–236. DOI: 10.1097/01.ieb.0000142782.97667.fc</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gass J.D.M. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol. 1995;119(6):752–759. DOI: 10.1016/s0002‑9394(14)72781‑3</mixed-citation><mixed-citation xml:lang="en">Gass J.D.M. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol. 1995;119(6):752–759. DOI: 10.1016/s0002‑9394(14)72781‑3</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Casuso L.A., Scott I.U., Flynn H.W. Jr., Gass J.D., Smiddy W.E., Lewis M.L., Schiffman J. Long‑term follow‑up of unoperated macular holes. Ophthalmology. 2001;108:1150–1155.</mixed-citation><mixed-citation xml:lang="en">Casuso L.A., Scott I.U., Flynn H.W. Jr., Gass J.D., Smiddy W.E., Lewis M.L., Schiffman J. Long‑term follow‑up of unoperated macular holes. Ophthalmology. 2001;108:1150–1155.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Unsal E., Cubuk M.O., Ciftci F. Preoperative prognostic factors for macular hole surgery: Which is better? Oman J Ophthalmol. 2019 Jan‑Apr;12(1):20–24. DOI: 10.4103/ojo.ojo_247_2017</mixed-citation><mixed-citation xml:lang="en">Unsal E., Cubuk M.O., Ciftci F. Preoperative prognostic factors for macular hole surgery: Which is better? Oman J Ophthalmol. 2019 Jan‑Apr;12(1):20–24. DOI: 10.4103/ojo.ojo_247_2017</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Christensen U.C., Kroyer K., Sander B., Larsen M., Henning V., Villumsen J., la Cour M. Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial. Br J Ophthalmol. 2009;93(8):1005–1015. DOI: 10.1136/bjo.2008.151266</mixed-citation><mixed-citation xml:lang="en">Christensen U.C., Kroyer K., Sander B., Larsen M., Henning V., Villumsen J., la Cour M. Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial. Br J Ophthalmol. 2009;93(8):1005–1015. DOI: 10.1136/bjo.2008.151266</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Al Sabti K., Kumar N., Azad R.V. Extended internal limiting membrane peeling in the management of unusually large macular holes. Ophthalmic Surg Lasers Imaging. 2009;40(2):185–187. DOI: 10.3928/15428877‑20090301‑03</mixed-citation><mixed-citation xml:lang="en">Al Sabti K., Kumar N., Azad R.V. Extended internal limiting membrane peeling in the management of unusually large macular holes. Ophthalmic Surg Lasers Imaging. 2009;40(2):185–187. DOI: 10.3928/15428877‑20090301‑03</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Самойлов А.Н., Хайбрахманов Т.Р, Фазлеева Г.А, П.А. Самойлова П.А. Идиопатический макулярный разрыв: история и современное состояние проблемы. Вестник офтальмологии. 2017;133(6):131–137. DOI: 10.17116/oftalma20171336131‑137</mixed-citation><mixed-citation xml:lang="en">Samojlov A.N., Hajbrahmanov T.R, Fazleeva G.A, Samojlova P.A. Idiopathic macular hole: history and status quo review. Annals of Ophthalmology = Vestnik oftal’mologii. 2017;133(6):131–137 (In Russ.). DOI: 10.17116/oftalma20171336131‑137</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Бикбов М.М., Файзрахманов Р.Р., Каланов М.Р. Комбинированный подход к оперативному лечению пациентов с пролиферативной стадией диабетической ретинопатии. Саратовский научно-медицинский журнал. 2017;13(2):338–345.</mixed-citation><mixed-citation xml:lang="en">Bikbov M.M., Fajzrahmanov R.R., Kalanov M.R. Clinical and functional assessment of the effectiveness of combined vitreoretinal  intervention in proliferative diabetic retinopathy. Saratov Journal of  Medical Scientific Research = Saratovskii nauchno-meditsinskii zhurnal. 2017;13(2):338–345 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Olsen T.W., Sternberg P. Jr, Capone A. Jr, Martin D.F., Lim J.I., Grossniklaus H.E., Aaberg T.M. Sr. Macular hole surgery using thrombin‑activated fibrinogen and selective removal of the internal limiting membrane. Retina. 1998;18(4):322–329. DOI: 10.1097/00006982‑199919050‑00031</mixed-citation><mixed-citation xml:lang="en">Olsen T.W., Sternberg P. Jr, Capone A. Jr, Martin D.F., Lim J.I., Grossniklaus H.E., Aaberg T.M. Sr. Macular hole surgery using thrombin‑activated fibrinogen and selective removal of the internal limiting membrane. Retina. 1998;18(4):322–329. DOI: 10.1097/00006982‑199919050‑00031</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Liggett P.E., Skolik D.S., Horio B., Saito Y., Alfaro V., Mieler W. Human autologous serum for the treatment of full‑thickness macular holes. A preliminary study. Ophthalmology. 1995;102(7):1071–1076. DOI: 10.1016/s0161‑6420 (95)30909‑8</mixed-citation><mixed-citation xml:lang="en">Liggett P.E., Skolik D.S., Horio B., Saito Y., Alfaro V., Mieler W. Human autologous serum for the treatment of full‑thickness macular holes. A preliminary study. Ophthalmology. 1995;102(7):1071–1076. DOI: 10.1016/s0161‑6420 (95)30909‑8</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hoerauf H., Kluter H., Joachimmeyer E., Roider J., Framme C., Schlenke P., Kirchner H., Lagua H. Results of vitrectomy and the no‑touch‑technique using autologous adjuvants in macular hole treatment. Int Ophthalmol. 2001;24(3):151–159. DOI: 10.1023/a:1021566806836</mixed-citation><mixed-citation xml:lang="en">Hoerauf H., Kluter H., Joachimmeyer E., Roider J., Framme C., Schlenke P., Kirchner H., Lagua H. Results of vitrectomy and the no‑touch‑technique using autologous adjuvants in macular hole treatment. Int Ophthalmol. 2001;24(3):151–159. DOI: 10.1023/a:1021566806836</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gaudric A., Massin P., Paques M., Santiago P.‑Y., Guez J.‑E., Le Gargasson J.‑F., Mundler O., Drouet L. Autologous platelet concentrate for the treatment of full‑thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995;233(9):549–554. DOI: 10.1007/bf00404704</mixed-citation><mixed-citation xml:lang="en">Gaudric A., Massin P., Paques M., Santiago P.‑Y., Guez J.‑E., Le Gargasson J.‑F., Mundler O., Drouet L. Autologous platelet concentrate for the treatment of full‑thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995;233(9):549–554. DOI: 10.1007/bf00404704</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Paques M., Chastang C., Mathis A., Sahel J., Massin P., Dosquet C., Korobelnik J.F., Le Gargasson J.F., Gaudric A. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double‑masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology. 1999;106(5):932–938. DOI: 10.1016/s0161‑6420(99)00512‑6</mixed-citation><mixed-citation xml:lang="en">Paques M., Chastang C., Mathis A., Sahel J., Massin P., Dosquet C., Korobelnik J.F., Le Gargasson J.F., Gaudric A. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double‑masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology. 1999;106(5):932–938. DOI: 10.1016/s0161‑6420(99)00512‑6</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Konstantinidis A., Hero M., Nanos P., Panos G.D. Efficacy of autologous platelets in macular hole surgery, Clin Ophthalmol. 2013(7):745–750. DOI: 10.2147/opth.s44440</mixed-citation><mixed-citation xml:lang="en">Konstantinidis A., Hero M., Nanos P., Panos G.D. Efficacy of autologous platelets in macular hole surgery, Clin Ophthalmol. 2013(7):745–750. DOI: 10.2147/opth.s44440</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Клейменов А.Ю., Казайкин В.Н. Способ хирургического лечения макулярного разрыва с интраоперационным применением перфторорганического соединения. Патент RU на изобретение 2685648, 04.05.18 Ссылка активна на 01.07.2019.</mixed-citation><mixed-citation xml:lang="en">Kleymenov A.Yu., Kazaykin V.N. A method for the surgical treatment of macular rupture with intraoperative use of an organofluorine compound. Patent RU 2685648, 04.05.18 Accessed 01.07.2019 (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
